Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: Guidelines for individual dosage recommendations

Journal Article · Thu Sep 01 04:00:00 EDT 1994 · Journal of Nuclear Medicine

OSTI ID:114863

Klerk, J M.H. de; Schip, A.D. van het; Zonnenberg, B A ^[1]

---

1. Univ. Hospital Utrecht (Netherlands); and others

A potential limitation of rhenium-186-1,1-hydroxyethylidene diphosphonate ({sup 186}Re-HEDP) therapy in patients with painful bone metastases is thrombocytopenia. Given the palliative character of this therapy, it is essential to be able to predict the degree of thrombocytopenia before therapy. Thus far, 39 prostatic cancer patients with multiple painful bone metastases were treated. Twenty-one patients underwent the therapy twice, resulting in 60 therapies. From the pre-therapy {sup 99m}Tc-HDP scintigram, the bone scan index (BSI) was determined as an index of the extent of bone involvement. The administered activity ranged from 1104 to 3479 MBq {sup 186}Re-HEDP. The platelet count was lowest 4 wk following therapy. From this value and the pretreatment level, the percentage decrease in the platelet count was determined (47%{+-}19%, range 14%-89%). The BSI ranged from 8 to 93. Regression analysis showed a functional relation (R = 0.78; p < 0.001) of the percentage of platelet decrease with BSI and administered activity normalized to standard body surface area. Using this relation, it is possible to predict thrombocytopenia by pretreatment bone scintigraphy and to adjust the dosage to each patient to avoid unacceptable toxicity. 27 refs., 4 figs., 1 tab.

• OSTI ID: 114863
• Journal Information: Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: 9 Vol. 35; ISSN 0161-5505; ISSN JNMEAQ
• Country of Publication: United States
• Language: English

Related Subjects

56 BIOLOGY AND MEDICINE
APPLIED STUDIES
BIOLOGICAL RADIATION EFFECTS
BLOOD PLATELETS
BONE TISSUES
METASTASES
PROSTATE
RADIOTHERAPY
SIDE EFFECTS
THROMBOPOIESIS